Prestige Consumer Healthcare (NYSE:PBH) Upgraded to Buy at StockNews.com

Prestige Consumer Healthcare (NYSE:PBH) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a report issued on Tuesday.

Other equities research analysts have also issued reports about the company. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. DA Davidson reaffirmed a “buy” rating and set a $95.00 price objective on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Jefferies Financial Group restated a “hold” rating and issued a $76.00 target price (up previously from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Finally, Sidoti downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a report on Monday, December 9th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $85.25.

Prestige Consumer Healthcare Stock Down 2.9 %

NYSE PBH opened at $74.67 on Tuesday. The stock has a 50 day moving average price of $80.50 and a 200-day moving average price of $74.07. Prestige Consumer Healthcare has a one year low of $58.18 and a one year high of $86.36. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. The company has a market capitalization of $3.69 billion, a P/E ratio of 18.17, a P/E/G ratio of 2.32 and a beta of 0.51.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, November 7th. The company reported $1.09 EPS for the quarter, meeting the consensus estimate of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The business had revenue of $283.79 million during the quarter, compared to analyst estimates of $282.09 million. During the same quarter last year, the business earned $1.07 earnings per share. Prestige Consumer Healthcare’s quarterly revenue was down .9% compared to the same quarter last year. As a group, equities analysts predict that Prestige Consumer Healthcare will post 4.44 EPS for the current fiscal year.

Insider Transactions at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 9,885 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $81.97, for a total value of $810,273.45. Following the completion of the sale, the senior vice president now directly owns 18,835 shares of the company’s stock, valued at $1,543,904.95. This represents a 34.42 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the transaction, the chief executive officer now owns 320,952 shares in the company, valued at approximately $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,810 shares of company stock worth $3,187,300. Insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Hedge funds have recently modified their holdings of the business. Geode Capital Management LLC lifted its stake in shares of Prestige Consumer Healthcare by 4.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock worth $95,678,000 after purchasing an additional 50,961 shares during the last quarter. Lombard Odier Asset Management USA Corp purchased a new stake in shares of Prestige Consumer Healthcare during the second quarter valued at about $550,000. Sequoia Financial Advisors LLC lifted its position in shares of Prestige Consumer Healthcare by 12.9% during the third quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company’s stock valued at $708,000 after buying an additional 1,120 shares during the last quarter. Barclays PLC boosted its holdings in shares of Prestige Consumer Healthcare by 346.3% in the 3rd quarter. Barclays PLC now owns 92,444 shares of the company’s stock valued at $6,665,000 after buying an additional 71,730 shares in the last quarter. Finally, Pinnacle Associates Ltd. grew its position in shares of Prestige Consumer Healthcare by 60.3% in the 3rd quarter. Pinnacle Associates Ltd. now owns 24,630 shares of the company’s stock worth $1,776,000 after buying an additional 9,269 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.